Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hyloris Teams Up With Vaneltix For Value-Added Interstitial Cystitis Pain Treatment

Results From Phase II Trials For Lidocaine/Heparin Candidate Could Be Ready By Late 2023

Executive Summary

Hyloris will make payments of up to $6.7m to Vaneltix, alongside a $500,000 loan, to support their collaboration to develop and commercialize Alenura, a first-line drug treatment for acute pain caused by interstitial cystitis that combines lidocaine and heparin.

You may also be interested in...



Hyloris On Track To Meet 2024 Target During Half-Year Update

Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.

Hyloris Raises €15m In Private Equity Offering

Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.

Hyloris Outlines Ambitious Growth Strategy During Full-Year Results

Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel